Patents Assigned to NATTOPHARMA AS
-
Patent number: 11911349Abstract: A method for rapidly improving cardiovascular function, reducing arterial stiffness and reversing calcification of a blood vessel in a mammal comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. Also a method for increasing endothelial nitric oxide production in mammals comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. The vitamin K can be administered together with additional substances such as vitamin D.Type: GrantFiled: April 1, 2019Date of Patent: February 27, 2024Assignee: NATTOPHARMA ASInventors: Stefan Chlopicki, Katarzyna Maresz, Anna Bar
-
Patent number: 9828323Abstract: Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R1 represents C1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z? and Z? represent H or one of Z? and Z? represents H and the other represents phenylsulfonyl group —SO2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates.Type: GrantFiled: October 11, 2013Date of Patent: November 28, 2017Assignee: Nattopharma R & D Ltd.Inventors: Krzysztof Krajewski, Andrzej Kutner, Jadwiga Dzikowska, Regina Gutowska, Marek Napiórkowski, Jerzy Winiarski, Marek Kubiszewski, Łukasz Jedynak, Jacek Morzycki, Stanislaw Witkowski, Aneta Baj, Piotr Wałejko
-
Publication number: 20160250160Abstract: Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.Type: ApplicationFiled: May 11, 2016Publication date: September 1, 2016Applicant: NATTOPHARMA ASAInventor: Cees VERMEER
-
Patent number: 9364447Abstract: Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.Type: GrantFiled: June 3, 2005Date of Patent: June 14, 2016Assignee: Nattopharma ASAInventor: Cees Vermeer
-
Publication number: 20150291498Abstract: Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R1 represents C1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z? and Z? represent H or one of Z? and Z? represents H and the other represents phenylsulfonyl group —SO2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates.Type: ApplicationFiled: October 11, 2013Publication date: October 15, 2015Applicant: NATTOPHARMA R&D LTDInventors: Krzysztof KRAJEWSKI, Andrzej KUTNER, Jadwiga DZIKOWSKA, Regina GUTOWSKA, Marek NAPIÓRKOWSKI, Jerzy WINIARSKI, Marek KUBISZEWSKI, Lukasz JEDYNAK, Jacek MORZYCKI, Stanislaw WITKOWSKI, Aneta BAJ, Piotr WALEJKO
-
Patent number: 8728553Abstract: A method for maintaining, optimizing, strengthening or promoting cardiovascular health of an individual, wherein an amount of menaquinone has been added to a food product such that the level of menaquinone is 5 to 5000 ?g per 100 g of food product.Type: GrantFiled: December 11, 2012Date of Patent: May 20, 2014Assignee: Nattopharma ASAInventors: Paul Thomas Quinlan, Cees Vermeer
-
Publication number: 20130172423Abstract: A food product comprising menaquinone at a level of 50 to 5,000 ?g per 100 g of product.Type: ApplicationFiled: December 11, 2012Publication date: July 4, 2013Applicant: NATTOPHARMA ASAInventor: NATTOPHARMA ASA
-
Publication number: 20100048704Abstract: A pharmaceutical and nutraceutical product is provided comprising vitamin K2 or a compound within the vitamin K2 class of compounds, optionally and preferably in combination with one or more polyunsaturated fatty acids, either in purified form or as a marine oil (i.e. fish and/or krill oil). Also provided is the use of vitamin K2 or a compound within the vitamin K2 class of compounds, preferably in combination with one or more polyunsaturated fatty acids, either in purified form or as a marine oil, in the treatment or prophylaxis of disorders related to bone, cartilage and the cardiovascular system. Preferred compounds within the vitamin K2 class of compounds are MK-7, MK-8, MK-9 and MK-10, in particular MK-7 or MK-9. The marine oil is preferably krill oil or fish oil.Type: ApplicationFiled: July 13, 2007Publication date: February 25, 2010Applicant: NATTOPHARMA ASAInventors: Cees Vermeer, Leon J. Schurgers, Jo Klaveness, Hogne Vik, Anne Bjornebye Vik, Stein Westbye